A 2026 juvenile rat study found that inactivating the ventral pallidum or stimulating nucleus accumbens GABA terminals in the ventral pallidum reduced social play behavior in both sexes, pointing to a specific reward-circuit pathway required for normal play expression.1 Research Highlights VP inactivation reduced play: bilateral muscimol infusion into the ventral pallidum reduced juvenile social …
A 2026 PET-fMRI study of 20 healthy adults found that GABAA receptor binding tracked speech-production brain activity across frontal, temporal, parietal, putaminal, supplementary motor, and cerebellar regions, with peak GABA-BOLD correlations reaching Rs = 0.9.1 Human speech control looks less like a pure motor-output problem and more like a task-specific balance between inhibition, dopamine, and …
A 2026 serum multiomics study linked occupational noise exposure to tinnitus severity mostly through metabolism: 10 metabolites, including GABA, fumaric acid, and steroid hormone precursors, statistically mediated 92% of the exposure-tinnitus association.1 The result is not a clinical blood test yet, but it pushes tinnitus biology beyond the ear-only frame toward a metabolism-immunity model that …
A 2026 medRxiv preprint did not find one simple autism excitation-inhibition signature. Bertelsen et al. found 2 EEG-derived E:I neurosubtypes in 286 autistic males: a 47% inhibition-dominant subtype with higher Hurst exponent and lower gamma, and a 53% excitation-dominant subtype with the opposite pattern.1 Research Highlights Two subtypes, opposite directions: in 286 autistic males ages …
Zuranolone, a novel antidepressant, shows promise in treating depression, as evidenced by a recent meta-analysis. A new study investigated zuranolone’s efficacy and safety, focusing on short-term rapid antidepressant effects. Highlights: Zuranolone Effectiveness: Demonstrated significant improvement in depression severity scores compared to placebo, with notable effects by day 15. Treatment-Emergent Adverse Events (TEAEs): Increased incidence in …
Allopregnanolone agonists represent a promising new class of medications for treating depressive disorders. Evidence suggests that allopregnanolone agonists exhibit rapid-onset of antidepressant action – particularly in women with postpartum depression (PPD). Key facts: Allopregnanolone is a neurosteroid that acts as a positive allosteric modulator of GABAA receptors and is decreased in depressive disorders. The allopregnanolone …
Xanax (alprazolam) is a drug of the benzodiazepine class originally developed by Upjohn, a Michigan-based pharmaceutical company (now a subsidiary of Pfizer). In the United States, Xanax first received FDA approval for the treatment of panic disorder and hit the market as a prescription medication in 1981. It eventually received subsequent FDA approval for the …